Print

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)


Treatment study for people with advanced cancer with an APC or AXIN1 mutation

About the Study

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation. REC-4881 is a type of targeted therapy drug known as a MEK1/2 inhibitor. 

NOTE: This study is no longer recruiting patients. 

 

This Study is Open To:

NOTE: This study is no longer recruiting patients. 

This Study is Not Open To:

NOTE: This study is no longer recruiting patients. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.